Interestingly, lone treatment with either PI3K or MAPK inhibitors did not result in a significant decrease in splenomegaly or most other MF phenotypes in the thrombopoietin receptor MPN animal models tested27,54. The gene discussed is MPL; the disease is myeloproliferative disorder.